SEC Form 4 · accession 0001209191-18-052485
Entasis Therapeutics Holdings Inc. · ETTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Gutch
Officer — CFO and Chief Business Officer
Period of report
Sep 25, 2018
Accepted (ET)
Sep 27, 2018 · 5:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001724344
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $15.00 | Sep 25, 2018 | A | 15,956 | A | — | Sep 24, 2028 | Common Stock | 15,956 | 15,956 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option shall vest on September 25, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.